The U.S. Patent and Trademark Office (USPTO) scored a recent victory, with the Federal Circuit determining that Sumitomo Pharma’s appeal concerning a decision that invalidated all claims of its patent is now moot. The patent, pertaining to a dosage regimen for a schizophrenia drug, expired just prior to the appeals court hearing oral arguments.
Sumitomo Pharma, a prominent Japanese pharmaceutical company, had appealed against the USPTO after the agency invalidated the claims of its patent. However, due to the patent’s expiration on the eve of oral arguments at the appeals court, the Federal Circuit deemed the company’s appeal no longer relevant.
The decision by the Federal Circuit is reflective of intricate patent laws and the importance of timeliness in defending patent rights. The sum of these events culminates to the USPTO’s benefit as it reinforces the agency’s standing in patent disputes.
For more details on this legal matter, you may go through the original article at Law360 here.